| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 32 | 2022 | 791 | 4.590 |
Why?
|
| Ritonavir | 12 | 2014 | 18 | 3.020 |
Why?
|
| Cost-Benefit Analysis | 43 | 2022 | 504 | 3.010 |
Why?
|
| Medicare | 19 | 2022 | 319 | 2.880 |
Why?
|
| Health Care Costs | 24 | 2018 | 346 | 2.730 |
Why?
|
| Stroke | 22 | 2022 | 2163 | 2.590 |
Why?
|
| United States | 77 | 2022 | 7367 | 2.370 |
Why?
|
| Insurance, Health | 13 | 2019 | 201 | 2.350 |
Why?
|
| Analgesics, Opioid | 9 | 2022 | 498 | 2.290 |
Why?
|
| Anti-HIV Agents | 12 | 2020 | 135 | 2.180 |
Why?
|
| Bariatric Surgery | 4 | 2020 | 90 | 2.040 |
Why?
|
| Humans | 204 | 2023 | 68618 | 2.030 |
Why?
|
| HIV Protease Inhibitors | 10 | 2014 | 25 | 1.970 |
Why?
|
| Telemedicine | 12 | 2022 | 700 | 1.800 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2014 | 28 | 1.790 |
Why?
|
| Lopinavir | 11 | 2014 | 18 | 1.750 |
Why?
|
| Pyrimidinones | 7 | 2010 | 26 | 1.650 |
Why?
|
| Markov Chains | 17 | 2014 | 133 | 1.630 |
Why?
|
| Female | 118 | 2022 | 38074 | 1.590 |
Why?
|
| Male | 112 | 2023 | 37321 | 1.530 |
Why?
|
| Emergency Service, Hospital | 12 | 2020 | 711 | 1.510 |
Why?
|
| Retrospective Studies | 53 | 2022 | 7277 | 1.480 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 172 | 1.480 |
Why?
|
| Hospitalization | 13 | 2019 | 978 | 1.460 |
Why?
|
| Stroke Rehabilitation | 6 | 2022 | 335 | 1.420 |
Why?
|
| Pyridines | 5 | 2012 | 261 | 1.410 |
Why?
|
| Aged | 66 | 2022 | 14862 | 1.400 |
Why?
|
| Medicaid | 9 | 2021 | 302 | 1.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2019 | 73 | 1.300 |
Why?
|
| Patient Discharge | 7 | 2021 | 294 | 1.280 |
Why?
|
| Frail Elderly | 2 | 2019 | 31 | 1.270 |
Why?
|
| Medication Errors | 3 | 2015 | 116 | 1.260 |
Why?
|
| Oligopeptides | 4 | 2012 | 152 | 1.240 |
Why?
|
| Adult | 73 | 2022 | 21403 | 1.230 |
Why?
|
| Health Services Accessibility | 10 | 2021 | 581 | 1.230 |
Why?
|
| HIV-1 | 7 | 2014 | 177 | 1.220 |
Why?
|
| Spinal Cord Injuries | 3 | 2019 | 551 | 1.210 |
Why?
|
| Middle Aged | 72 | 2020 | 21147 | 1.180 |
Why?
|
| Quality-Adjusted Life Years | 17 | 2017 | 106 | 1.170 |
Why?
|
| Adolescent | 51 | 2022 | 8912 | 1.170 |
Why?
|
| Economic Recession | 2 | 2018 | 8 | 1.140 |
Why?
|
| Drug Prescriptions | 5 | 2021 | 135 | 1.130 |
Why?
|
| Brain Ischemia | 6 | 2020 | 665 | 1.120 |
Why?
|
| Costs and Cost Analysis | 13 | 2018 | 193 | 1.120 |
Why?
|
| Rehabilitation Centers | 4 | 2019 | 46 | 1.090 |
Why?
|
| Aged, 80 and over | 31 | 2019 | 4848 | 1.080 |
Why?
|
| Rho(D) Immune Globulin | 3 | 2013 | 9 | 1.070 |
Why?
|
| Polypharmacy | 3 | 2018 | 31 | 1.060 |
Why?
|
| Length of Stay | 14 | 2020 | 780 | 1.000 |
Why?
|
| HIV Seropositivity | 3 | 2014 | 66 | 1.000 |
Why?
|
| Models, Economic | 7 | 2013 | 69 | 0.990 |
Why?
|
| Spiro Compounds | 2 | 2022 | 14 | 0.990 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 694 | 0.970 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 148 | 0.970 |
Why?
|
| Cost of Illness | 12 | 2018 | 206 | 0.960 |
Why?
|
| Sepsis | 6 | 2016 | 233 | 0.960 |
Why?
|
| Young Adult | 27 | 2020 | 5717 | 0.920 |
Why?
|
| Asthma | 6 | 2019 | 345 | 0.920 |
Why?
|
| Rh Isoimmunization | 2 | 2013 | 6 | 0.920 |
Why?
|
| Depressive Disorder, Major | 3 | 2019 | 439 | 0.920 |
Why?
|
| Genotyping Techniques | 2 | 2013 | 19 | 0.910 |
Why?
|
| Primary Health Care | 4 | 2021 | 703 | 0.900 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 848 | 0.880 |
Why?
|
| Unnecessary Procedures | 2 | 2013 | 49 | 0.880 |
Why?
|
| Ambulatory Care | 6 | 2022 | 340 | 0.850 |
Why?
|
| Surveys and Questionnaires | 14 | 2020 | 2800 | 0.850 |
Why?
|
| Cohort Studies | 16 | 2020 | 2358 | 0.840 |
Why?
|
| Thrombolytic Therapy | 6 | 2020 | 233 | 0.830 |
Why?
|
| Tissue Plasminogen Activator | 7 | 2020 | 296 | 0.810 |
Why?
|
| Pemphigus | 1 | 2021 | 12 | 0.790 |
Why?
|
| Pharmacy | 1 | 2022 | 26 | 0.790 |
Why?
|
| South Carolina | 21 | 2021 | 2752 | 0.780 |
Why?
|
| Pediatrics | 3 | 2015 | 341 | 0.770 |
Why?
|
| Acute Pain | 1 | 2021 | 35 | 0.750 |
Why?
|
| Mass Screening | 7 | 2020 | 843 | 0.750 |
Why?
|
| Endovascular Procedures | 4 | 2020 | 366 | 0.750 |
Why?
|
| Decision Support Techniques | 10 | 2018 | 191 | 0.740 |
Why?
|
| Health Resources | 2 | 2018 | 76 | 0.740 |
Why?
|
| Databases, Factual | 15 | 2019 | 622 | 0.740 |
Why?
|
| Occupational Therapy | 1 | 2022 | 80 | 0.740 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.740 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.730 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2021 | 59 | 0.720 |
Why?
|
| Sulfonamides | 4 | 2014 | 141 | 0.720 |
Why?
|
| Risk Adjustment | 2 | 2017 | 49 | 0.710 |
Why?
|
| Disability Evaluation | 6 | 2018 | 298 | 0.710 |
Why?
|
| Comorbidity | 10 | 2019 | 1426 | 0.700 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 44 | 0.690 |
Why?
|
| Geographic Atrophy | 1 | 2019 | 5 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 931 | 0.680 |
Why?
|
| Health Expenditures | 7 | 2018 | 170 | 0.680 |
Why?
|
| Child | 27 | 2022 | 6405 | 0.680 |
Why?
|
| Risk-Taking | 2 | 2020 | 210 | 0.670 |
Why?
|
| Practice Guidelines as Topic | 9 | 2019 | 772 | 0.660 |
Why?
|
| Critical Care | 4 | 2020 | 263 | 0.640 |
Why?
|
| Diuretics | 1 | 2019 | 97 | 0.640 |
Why?
|
| Drug Therapy, Combination | 11 | 2017 | 649 | 0.640 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 454 | 0.620 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 157 | 0.610 |
Why?
|
| Frailty | 1 | 2018 | 34 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 1085 | 0.600 |
Why?
|
| Age Factors | 10 | 2019 | 1864 | 0.600 |
Why?
|
| Drug Combinations | 8 | 2017 | 304 | 0.600 |
Why?
|
| Fibrinolytic Agents | 5 | 2020 | 377 | 0.600 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 1851 | 0.600 |
Why?
|
| Patient Participation | 3 | 2020 | 146 | 0.590 |
Why?
|
| Social Participation | 1 | 2017 | 16 | 0.590 |
Why?
|
| Social Skills | 1 | 2017 | 14 | 0.590 |
Why?
|
| Zidovudine | 6 | 2000 | 27 | 0.580 |
Why?
|
| Patient Readmission | 6 | 2018 | 267 | 0.570 |
Why?
|
| Chronic Disease | 3 | 2016 | 1330 | 0.570 |
Why?
|
| Quality of Life | 13 | 2022 | 1515 | 0.570 |
Why?
|
| Acetaminophen | 1 | 2017 | 111 | 0.560 |
Why?
|
| Deglutition Disorders | 3 | 2022 | 297 | 0.550 |
Why?
|
| Quality Improvement | 3 | 2020 | 413 | 0.550 |
Why?
|
| Pandemics | 6 | 2022 | 352 | 0.550 |
Why?
|
| Guideline Adherence | 3 | 2016 | 287 | 0.530 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 46 | 0.530 |
Why?
|
| Schools | 1 | 2017 | 156 | 0.530 |
Why?
|
| Treatment Outcome | 24 | 2021 | 7029 | 0.530 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2017 | 186 | 0.530 |
Why?
|
| Quality of Health Care | 4 | 2017 | 322 | 0.530 |
Why?
|
| Social Environment | 1 | 2017 | 182 | 0.530 |
Why?
|
| Sex Factors | 7 | 2019 | 1266 | 0.520 |
Why?
|
| Rape | 1 | 2017 | 180 | 0.520 |
Why?
|
| Violence | 2 | 2017 | 275 | 0.510 |
Why?
|
| Autism Spectrum Disorder | 1 | 2017 | 111 | 0.510 |
Why?
|
| Statistics as Topic | 2 | 2015 | 219 | 0.500 |
Why?
|
| Infant | 14 | 2021 | 2891 | 0.500 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 84 | 0.490 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 176 | 0.480 |
Why?
|
| Risk Factors | 18 | 2022 | 5731 | 0.480 |
Why?
|
| Drug Overdose | 1 | 2015 | 67 | 0.480 |
Why?
|
| Alzheimer Disease | 2 | 2018 | 565 | 0.470 |
Why?
|
| Metronidazole | 1 | 2014 | 28 | 0.470 |
Why?
|
| Virology | 1 | 2014 | 11 | 0.470 |
Why?
|
| Disease Progression | 1 | 2018 | 1038 | 0.470 |
Why?
|
| Trichomonas vaginalis | 1 | 2014 | 22 | 0.470 |
Why?
|
| Health Status | 2 | 2019 | 429 | 0.470 |
Why?
|
| Cytological Techniques | 1 | 2014 | 23 | 0.470 |
Why?
|
| Logistic Models | 14 | 2019 | 1420 | 0.470 |
Why?
|
| Trichomonas Vaginitis | 1 | 2014 | 25 | 0.470 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.470 |
Why?
|
| Time Factors | 11 | 2018 | 4655 | 0.470 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 44 | 0.460 |
Why?
|
| Infant, Newborn | 14 | 2021 | 2455 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2021 | 504 | 0.460 |
Why?
|
| Referral and Consultation | 1 | 2016 | 383 | 0.460 |
Why?
|
| Cognition | 1 | 2018 | 513 | 0.460 |
Why?
|
| Aphasia | 2 | 2014 | 119 | 0.450 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 307 | 0.450 |
Why?
|
| Electronic Health Records | 5 | 2023 | 374 | 0.450 |
Why?
|
| Immunization Programs | 3 | 2008 | 25 | 0.450 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.450 |
Why?
|
| Cost Savings | 7 | 2017 | 110 | 0.450 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 378 | 0.450 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 42 | 0.450 |
Why?
|
| Longitudinal Studies | 6 | 2019 | 1054 | 0.440 |
Why?
|
| Coronary Disease | 4 | 2009 | 358 | 0.440 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 225 | 0.440 |
Why?
|
| Child, Preschool | 15 | 2021 | 3187 | 0.430 |
Why?
|
| Administration, Inhalation | 2 | 2017 | 187 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.430 |
Why?
|
| Circumcision, Male | 1 | 2012 | 12 | 0.430 |
Why?
|
| Outpatients | 4 | 2018 | 127 | 0.420 |
Why?
|
| Propensity Score | 4 | 2018 | 117 | 0.420 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 166 | 0.420 |
Why?
|
| Hospitals | 4 | 2022 | 265 | 0.410 |
Why?
|
| Heart Failure | 3 | 2019 | 1180 | 0.410 |
Why?
|
| Multivariate Analysis | 12 | 2017 | 1046 | 0.400 |
Why?
|
| Dietary Fiber | 1 | 2012 | 37 | 0.400 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 37 | 0.400 |
Why?
|
| Gastrostomy | 3 | 2018 | 110 | 0.390 |
Why?
|
| Health Surveys | 2 | 2018 | 489 | 0.390 |
Why?
|
| Hospital Mortality | 4 | 2020 | 384 | 0.390 |
Why?
|
| Thiophenes | 2 | 2022 | 76 | 0.390 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 2279 | 0.380 |
Why?
|
| Enteral Nutrition | 3 | 2018 | 157 | 0.380 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 1242 | 0.380 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2021 | 34 | 0.380 |
Why?
|
| Wounds and Injuries | 4 | 2010 | 334 | 0.370 |
Why?
|
| Public Health | 1 | 2012 | 201 | 0.370 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2014 | 98 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 5 | 2016 | 365 | 0.370 |
Why?
|
| Hospital Costs | 6 | 2014 | 117 | 0.370 |
Why?
|
| Cesarean Section, Repeat | 1 | 2010 | 4 | 0.360 |
Why?
|
| Medication Systems, Hospital | 1 | 2010 | 19 | 0.360 |
Why?
|
| Decision Trees | 5 | 2018 | 74 | 0.360 |
Why?
|
| Skilled Nursing Facilities | 3 | 2019 | 30 | 0.360 |
Why?
|
| Influenza, Human | 2 | 2008 | 79 | 0.360 |
Why?
|
| International Classification of Diseases | 3 | 2019 | 85 | 0.350 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 38 | 0.350 |
Why?
|
| Incidence | 7 | 2022 | 1603 | 0.350 |
Why?
|
| Alcoholism | 4 | 2010 | 1109 | 0.350 |
Why?
|
| Morphine | 2 | 2022 | 76 | 0.350 |
Why?
|
| Inpatients | 3 | 2019 | 208 | 0.340 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 95 | 0.340 |
Why?
|
| Models, Statistical | 8 | 2018 | 448 | 0.340 |
Why?
|
| Hospital Charges | 2 | 2008 | 60 | 0.340 |
Why?
|
| Patient Navigation | 3 | 2020 | 30 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2018 | 468 | 0.340 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 955 | 0.340 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2010 | 56 | 0.330 |
Why?
|
| Atazanavir Sulfate | 4 | 2012 | 6 | 0.330 |
Why?
|
| Disabled Persons | 2 | 2020 | 94 | 0.330 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 3259 | 0.330 |
Why?
|
| Activities of Daily Living | 5 | 2020 | 319 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2016 | 161 | 0.320 |
Why?
|
| Drug Costs | 8 | 2019 | 87 | 0.320 |
Why?
|
| Patient Admission | 3 | 2019 | 99 | 0.320 |
Why?
|
| Viral Load | 6 | 2020 | 127 | 0.320 |
Why?
|
| Pyrones | 1 | 2008 | 4 | 0.320 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 6 | 0.320 |
Why?
|
| Fees, Pharmaceutical | 3 | 2007 | 7 | 0.320 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2019 | 56 | 0.310 |
Why?
|
| Influenza Vaccines | 2 | 2008 | 56 | 0.310 |
Why?
|
| Prognosis | 6 | 2020 | 2093 | 0.310 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2018 | 47 | 0.310 |
Why?
|
| Europe | 6 | 2017 | 196 | 0.310 |
Why?
|
| Survival Analysis | 6 | 2019 | 714 | 0.310 |
Why?
|
| Decision Making | 3 | 2015 | 410 | 0.300 |
Why?
|
| Psychometrics | 4 | 2018 | 514 | 0.300 |
Why?
|
| Survival Rate | 6 | 2012 | 1056 | 0.300 |
Why?
|
| Specialization | 2 | 2019 | 66 | 0.300 |
Why?
|
| Kidney Transplantation | 5 | 2016 | 839 | 0.290 |
Why?
|
| Physical Therapy Modalities | 2 | 2020 | 133 | 0.290 |
Why?
|
| Lamivudine | 3 | 2011 | 24 | 0.290 |
Why?
|
| Antihypertensive Agents | 3 | 2009 | 498 | 0.280 |
Why?
|
| Likelihood Functions | 2 | 2018 | 106 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2021 | 33 | 0.280 |
Why?
|
| Computer Simulation | 3 | 2009 | 706 | 0.280 |
Why?
|
| Patient Credit and Collection | 1 | 2006 | 7 | 0.270 |
Why?
|
| Australia | 2 | 2017 | 235 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2019 | 123 | 0.270 |
Why?
|
| Gastroscopy | 2 | 2016 | 45 | 0.270 |
Why?
|
| Rituximab | 2 | 2021 | 61 | 0.270 |
Why?
|
| Models, Econometric | 5 | 2009 | 26 | 0.260 |
Why?
|
| Odds Ratio | 5 | 2018 | 880 | 0.260 |
Why?
|
| Insurance Claim Review | 4 | 2019 | 39 | 0.260 |
Why?
|
| Prevalence | 8 | 2019 | 1619 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2020 | 335 | 0.260 |
Why?
|
| Pregnancy | 6 | 2013 | 2334 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 511 | 0.260 |
Why?
|
| Hypertension, Pulmonary | 2 | 2009 | 232 | 0.250 |
Why?
|
| Research Design | 2 | 2023 | 729 | 0.250 |
Why?
|
| Sertraline | 1 | 2005 | 62 | 0.250 |
Why?
|
| Residence Characteristics | 2 | 2019 | 252 | 0.240 |
Why?
|
| Accidents, Occupational | 1 | 2004 | 16 | 0.240 |
Why?
|
| Hearing Loss | 2 | 2018 | 154 | 0.240 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2009 | 413 | 0.240 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 334 | 0.240 |
Why?
|
| Electromagnetic Phenomena | 1 | 2004 | 25 | 0.240 |
Why?
|
| Health Literacy | 2 | 2015 | 63 | 0.240 |
Why?
|
| Agriculture | 1 | 2004 | 54 | 0.240 |
Why?
|
| Risk Assessment | 6 | 2019 | 2007 | 0.230 |
Why?
|
| Employment | 2 | 2019 | 154 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 92 | 0.230 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.230 |
Why?
|
| Diffusion of Innovation | 2 | 2013 | 102 | 0.230 |
Why?
|
| Epoprostenol | 1 | 2003 | 71 | 0.230 |
Why?
|
| Community Mental Health Services | 1 | 2004 | 65 | 0.220 |
Why?
|
| Medical Records | 1 | 2004 | 121 | 0.220 |
Why?
|
| Documentation | 2 | 2019 | 83 | 0.220 |
Why?
|
| Reproducibility of Results | 7 | 2017 | 2077 | 0.220 |
Why?
|
| Regression Analysis | 6 | 2018 | 737 | 0.220 |
Why?
|
| Infertility, Male | 1 | 2023 | 35 | 0.210 |
Why?
|
| Mental Processes | 1 | 2023 | 22 | 0.210 |
Why?
|
| Florida | 5 | 2017 | 221 | 0.210 |
Why?
|
| Disease Management | 2 | 2015 | 248 | 0.210 |
Why?
|
| Intensive Care Units | 4 | 2021 | 344 | 0.210 |
Why?
|
| Wet Macular Degeneration | 1 | 2022 | 2 | 0.210 |
Why?
|
| Private Sector | 2 | 2019 | 19 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 951 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 189 | 0.210 |
Why?
|
| Depression | 3 | 2022 | 943 | 0.210 |
Why?
|
| Personal Protective Equipment | 1 | 2022 | 27 | 0.200 |
Why?
|
| Cause of Death | 3 | 2014 | 241 | 0.200 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 214 | 0.200 |
Why?
|
| Sexual Behavior | 2 | 2020 | 183 | 0.200 |
Why?
|
| Health Status Disparities | 2 | 2016 | 326 | 0.200 |
Why?
|
| Choroidal Neovascularization | 1 | 2022 | 35 | 0.200 |
Why?
|
| Organ Dysfunction Scores | 1 | 2021 | 13 | 0.200 |
Why?
|
| Canada | 4 | 2017 | 267 | 0.190 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.190 |
Why?
|
| Postoperative Complications | 5 | 2020 | 1615 | 0.190 |
Why?
|
| Physical Therapists | 1 | 2021 | 21 | 0.190 |
Why?
|
| Health Facilities | 1 | 2021 | 36 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2021 | 87 | 0.190 |
Why?
|
| Medically Underserved Area | 3 | 2016 | 85 | 0.180 |
Why?
|
| Neuropsychological Tests | 2 | 2018 | 517 | 0.180 |
Why?
|
| Social Networking | 1 | 2020 | 14 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 1070 | 0.180 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 34 | 0.180 |
Why?
|
| Nevirapine | 1 | 2000 | 7 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 767 | 0.180 |
Why?
|
| Aftercare | 2 | 2021 | 114 | 0.180 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2019 | 6 | 0.180 |
Why?
|
| Marijuana Use | 1 | 2020 | 35 | 0.180 |
Why?
|
| Tonsillectomy | 1 | 2021 | 69 | 0.170 |
Why?
|
| Laboratories, Hospital | 2 | 1998 | 4 | 0.170 |
Why?
|
| Population Health | 1 | 2020 | 12 | 0.170 |
Why?
|
| Medical Informatics | 1 | 2020 | 71 | 0.170 |
Why?
|
| Home Care Services | 1 | 2020 | 84 | 0.170 |
Why?
|
| Emergency Medicine | 1 | 2020 | 88 | 0.170 |
Why?
|
| Sexual Partners | 1 | 2020 | 106 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 77 | 0.170 |
Why?
|
| Exudates and Transudates | 1 | 2019 | 25 | 0.170 |
Why?
|
| United Kingdom | 2 | 2012 | 152 | 0.170 |
Why?
|
| Electroconvulsive Therapy | 1 | 2004 | 402 | 0.170 |
Why?
|
| Health Behavior | 2 | 2020 | 458 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 59 | 0.170 |
Why?
|
| Appalachian Region | 1 | 2019 | 6 | 0.170 |
Why?
|
| Kentucky | 1 | 2019 | 13 | 0.170 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Low Back Pain | 1 | 2019 | 45 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 91 | 0.160 |
Why?
|
| Age Distribution | 2 | 2012 | 320 | 0.160 |
Why?
|
| Focus Groups | 3 | 2014 | 247 | 0.160 |
Why?
|
| Ureteral Obstruction | 1 | 2018 | 25 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2020 | 205 | 0.160 |
Why?
|
| Nurses | 1 | 2019 | 53 | 0.160 |
Why?
|
| New York | 2 | 2018 | 223 | 0.160 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2019 | 53 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2019 | 94 | 0.160 |
Why?
|
| Methamphetamine | 1 | 2020 | 132 | 0.160 |
Why?
|
| Antiviral Agents | 3 | 1996 | 211 | 0.160 |
Why?
|
| Neurology | 1 | 2019 | 43 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2019 | 77 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2020 | 183 | 0.160 |
Why?
|
| Rotator Cuff Injuries | 1 | 2019 | 32 | 0.160 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2018 | 17 | 0.160 |
Why?
|
| Hospitals, Teaching | 2 | 2017 | 65 | 0.160 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 47 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 197 | 0.160 |
Why?
|
| Mandatory Testing | 1 | 1998 | 3 | 0.160 |
Why?
|
| Tetralogy of Fallot | 1 | 2018 | 43 | 0.150 |
Why?
|
| Skull Fractures | 1 | 2018 | 17 | 0.150 |
Why?
|
| Point-of-Care Systems | 2 | 1998 | 115 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 27 | 0.150 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 119 | 0.150 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 19 | 0.150 |
Why?
|
| AIDS Serodiagnosis | 1 | 1998 | 17 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1998 | 14 | 0.150 |
Why?
|
| Diagnosis-Related Groups | 3 | 2006 | 28 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2004 | 824 | 0.150 |
Why?
|
| Constipation | 1 | 2018 | 32 | 0.150 |
Why?
|
| Intellectual Disability | 1 | 2019 | 114 | 0.150 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 51 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2019 | 101 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 298 | 0.150 |
Why?
|
| Antidepressive Agents | 2 | 2009 | 216 | 0.150 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2018 | 48 | 0.150 |
Why?
|
| Hospitals, Rural | 2 | 2020 | 43 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1998 | 52 | 0.150 |
Why?
|
| Independent Living | 1 | 2018 | 44 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 445 | 0.150 |
Why?
|
| Reoperation | 1 | 2019 | 467 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 1 | 2018 | 41 | 0.140 |
Why?
|
| Fibromyalgia | 1 | 2017 | 29 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2019 | 222 | 0.140 |
Why?
|
| Parents | 2 | 2017 | 312 | 0.140 |
Why?
|
| Living Donors | 2 | 2016 | 160 | 0.140 |
Why?
|
| Darunavir | 2 | 2014 | 2 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2017 | 3705 | 0.140 |
Why?
|
| Nephrologists | 1 | 2016 | 7 | 0.140 |
Why?
|
| Endocrinologists | 1 | 2016 | 12 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1745 | 0.140 |
Why?
|
| Rheumatologists | 1 | 2016 | 14 | 0.140 |
Why?
|
| DNA, Viral | 2 | 2014 | 114 | 0.140 |
Why?
|
| Anesthesia, General | 2 | 2014 | 86 | 0.140 |
Why?
|
| Aorta, Thoracic | 2 | 2015 | 211 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 76 | 0.140 |
Why?
|
| Data Collection | 4 | 2015 | 420 | 0.140 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1753 | 0.140 |
Why?
|
| Mental Health | 1 | 2019 | 278 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2017 | 86 | 0.140 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 73 | 0.130 |
Why?
|
| Vaccines | 1 | 1995 | 21 | 0.130 |
Why?
|
| Health Promotion | 1 | 2020 | 407 | 0.130 |
Why?
|
| Dosage Forms | 1 | 2015 | 20 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 1998 | 218 | 0.130 |
Why?
|
| Drug Labeling | 1 | 2015 | 32 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 12 | 0.130 |
Why?
|
| Delphi Technique | 1 | 2015 | 62 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 18 | 0.130 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2015 | 9 | 0.130 |
Why?
|
| Health Services | 1 | 2016 | 87 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 514 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2020 | 1451 | 0.130 |
Why?
|
| Zalcitabine | 1 | 1994 | 4 | 0.120 |
Why?
|
| Morbidity | 1 | 2015 | 130 | 0.120 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2014 | 7 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1995 | 61 | 0.120 |
Why?
|
| Sickness Impact Profile | 2 | 2013 | 27 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2016 | 113 | 0.120 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2015 | 141 | 0.120 |
Why?
|
| California | 1 | 2014 | 99 | 0.120 |
Why?
|
| Self Care | 1 | 2017 | 253 | 0.120 |
Why?
|
| Dysarthria | 1 | 2014 | 9 | 0.120 |
Why?
|
| Drug Resistance, Viral | 1 | 2014 | 14 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2017 | 64 | 0.120 |
Why?
|
| Nursing Homes | 1 | 2014 | 54 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 1506 | 0.120 |
Why?
|
| Night Care | 1 | 2014 | 4 | 0.120 |
Why?
|
| Coinfection | 1 | 2014 | 30 | 0.120 |
Why?
|
| Thinking | 1 | 2014 | 30 | 0.120 |
Why?
|
| Urban Health | 1 | 2014 | 49 | 0.120 |
Why?
|
| Students, Health Occupations | 1 | 2014 | 33 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2009 | 1738 | 0.120 |
Why?
|
| Rural Health | 1 | 2014 | 66 | 0.120 |
Why?
|
| Hospitalists | 1 | 2014 | 21 | 0.110 |
Why?
|
| Social Class | 3 | 2016 | 127 | 0.110 |
Why?
|
| Caregivers | 1 | 2017 | 365 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 47 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2014 | 112 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 279 | 0.110 |
Why?
|
| Life Expectancy | 2 | 2009 | 51 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2014 | 104 | 0.110 |
Why?
|
| Problem-Based Learning | 1 | 2014 | 72 | 0.110 |
Why?
|
| Renal Replacement Therapy | 3 | 2003 | 40 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2013 | 59 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2013 | 67 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2014 | 113 | 0.110 |
Why?
|
| Proctoscopy | 1 | 2012 | 4 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 188 | 0.110 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2014 | 138 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 237 | 0.100 |
Why?
|
| Linear Models | 3 | 2023 | 521 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 53 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2014 | 311 | 0.100 |
Why?
|
| Kenya | 1 | 2011 | 26 | 0.100 |
Why?
|
| Continuity of Patient Care | 3 | 2022 | 170 | 0.100 |
Why?
|
| Uganda | 1 | 2011 | 41 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2012 | 104 | 0.100 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2004 | 85 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2012 | 98 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 402 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 1992 | 117 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 800 | 0.100 |
Why?
|
| Qualitative Research | 3 | 2022 | 369 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2011 | 42 | 0.100 |
Why?
|
| Health Personnel | 1 | 2014 | 286 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2006 | 435 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 940 | 0.100 |
Why?
|
| Lorazepam | 3 | 2006 | 54 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 579 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2011 | 97 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 447 | 0.090 |
Why?
|
| Budgets | 2 | 2009 | 12 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 369 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 807 | 0.090 |
Why?
|
| Quadriceps Muscle | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cerebral Palsy | 1 | 2010 | 24 | 0.090 |
Why?
|
| Antipsychotic Agents | 3 | 2008 | 247 | 0.090 |
Why?
|
| South Africa | 1 | 2010 | 45 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2010 | 26 | 0.090 |
Why?
|
| Pilot Projects | 5 | 2020 | 1342 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2010 | 62 | 0.090 |
Why?
|
| Virginia | 1 | 2010 | 45 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 226 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 756 | 0.090 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2010 | 31 | 0.090 |
Why?
|
| Transferrin | 1 | 2010 | 94 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 226 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 157 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2008 | 349 | 0.080 |
Why?
|
| Calorimetry, Indirect | 1 | 2009 | 12 | 0.080 |
Why?
|
| Basal Metabolism | 1 | 2009 | 22 | 0.080 |
Why?
|
| Economics, Pharmaceutical | 1 | 2009 | 5 | 0.080 |
Why?
|
| Mathematics | 1 | 2009 | 83 | 0.080 |
Why?
|
| Gestational Age | 1 | 2010 | 389 | 0.080 |
Why?
|
| Thrombectomy | 1 | 2011 | 238 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2008 | 502 | 0.080 |
Why?
|
| Neoplasms | 1 | 2020 | 1667 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2012 | 631 | 0.080 |
Why?
|
| Vincristine | 1 | 2008 | 44 | 0.080 |
Why?
|
| Anti-Anxiety Agents | 2 | 2006 | 107 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 778 | 0.080 |
Why?
|
| Ontario | 2 | 2006 | 24 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2009 | 223 | 0.080 |
Why?
|
| Chronic Pain | 2 | 2020 | 110 | 0.080 |
Why?
|
| Energy Intake | 1 | 2009 | 123 | 0.080 |
Why?
|
| Ethanol | 2 | 2006 | 893 | 0.080 |
Why?
|
| Remission Induction | 1 | 2008 | 111 | 0.080 |
Why?
|
| Prednisone | 1 | 2008 | 104 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 129 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 186 | 0.080 |
Why?
|
| Medical Audit | 1 | 2008 | 44 | 0.080 |
Why?
|
| Mammography | 1 | 1991 | 310 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 129 | 0.080 |
Why?
|
| Group Processes | 1 | 2008 | 42 | 0.070 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 63 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 169 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2008 | 107 | 0.070 |
Why?
|
| Medically Uninsured | 1 | 2008 | 99 | 0.070 |
Why?
|
| France | 1 | 2007 | 26 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2008 | 130 | 0.070 |
Why?
|
| Spain | 1 | 2007 | 34 | 0.070 |
Why?
|
| Italy | 1 | 2007 | 36 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 231 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 157 | 0.070 |
Why?
|
| Social Justice | 1 | 2006 | 32 | 0.070 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2005 | 24 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2005 | 782 | 0.060 |
Why?
|
| Physician's Role | 1 | 2006 | 116 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 468 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2004 | 4 | 0.060 |
Why?
|
| Illinois | 1 | 2004 | 5 | 0.060 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2004 | 71 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2005 | 219 | 0.060 |
Why?
|
| Goals | 2 | 2020 | 65 | 0.060 |
Why?
|
| Periodicity | 1 | 2004 | 43 | 0.060 |
Why?
|
| Occupational Health | 1 | 2004 | 41 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2004 | 242 | 0.060 |
Why?
|
| Hypertension | 2 | 2020 | 1535 | 0.060 |
Why?
|
| Patient Care | 1 | 2004 | 61 | 0.060 |
Why?
|
| Mental Health Services | 1 | 2006 | 199 | 0.060 |
Why?
|
| Monte Carlo Method | 2 | 2021 | 124 | 0.060 |
Why?
|
| Workload | 1 | 2004 | 103 | 0.060 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2023 | 1 | 0.050 |
Why?
|
| Sperm Retrieval | 1 | 2023 | 2 | 0.050 |
Why?
|
| Survivors | 2 | 2021 | 256 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 29 | 0.050 |
Why?
|
| Naltrexone | 1 | 2004 | 195 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2023 | 29 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 37 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2023 | 75 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 342 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2017 | 190 | 0.050 |
Why?
|
| Carbamazepine | 1 | 2002 | 108 | 0.050 |
Why?
|
| Dabigatran | 1 | 2022 | 35 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 124 | 0.050 |
Why?
|
| Retinal Pigments | 1 | 2022 | 61 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 371 | 0.050 |
Why?
|
| Thrombin | 1 | 2022 | 117 | 0.050 |
Why?
|
| Social Support | 2 | 2014 | 423 | 0.050 |
Why?
|
| Obesity | 1 | 2009 | 1076 | 0.050 |
Why?
|
| Sex Distribution | 3 | 2012 | 274 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 69 | 0.050 |
Why?
|
| Ecosystem | 1 | 2021 | 54 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2002 | 132 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 219 | 0.050 |
Why?
|
| Clonidine | 3 | 2006 | 66 | 0.050 |
Why?
|
| Community Pharmacy Services | 1 | 2000 | 11 | 0.050 |
Why?
|
| Poverty | 1 | 2002 | 219 | 0.050 |
Why?
|
| Prescription Drug Misuse | 1 | 2021 | 35 | 0.050 |
Why?
|
| Haloperidol | 3 | 2006 | 95 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1452 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 2 | 2005 | 68 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2002 | 223 | 0.050 |
Why?
|
| Didanosine | 1 | 2000 | 3 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 33 | 0.050 |
Why?
|
| Developed Countries | 1 | 2000 | 8 | 0.050 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 14 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2020 | 64 | 0.050 |
Why?
|
| Occult Blood | 1 | 2000 | 48 | 0.050 |
Why?
|
| Survival | 1 | 2000 | 22 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2020 | 35 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 546 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2020 | 21 | 0.040 |
Why?
|
| Government Programs | 1 | 2000 | 16 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 58 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2000 | 48 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 93 | 0.040 |
Why?
|
| Cerebral Revascularization | 1 | 2020 | 45 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2020 | 137 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 72 | 0.040 |
Why?
|
| Resuscitation | 1 | 2020 | 77 | 0.040 |
Why?
|
| Phenotype | 1 | 2023 | 947 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 431 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1553 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Sexual Health | 1 | 2019 | 6 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Neurologists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 240 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 15 | 0.040 |
Why?
|
| Sex Education | 1 | 2019 | 20 | 0.040 |
Why?
|
| Leadership | 1 | 2020 | 136 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 146 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.040 |
Why?
|
| Rotator Cuff | 1 | 2019 | 25 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 50 | 0.040 |
Why?
|
| Kidney Pelvis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Ureter | 1 | 2018 | 16 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 119 | 0.040 |
Why?
|
| Hemiarthroplasty | 1 | 2018 | 7 | 0.040 |
Why?
|
| Arthroscopy | 1 | 2019 | 95 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 328 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 23 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 1998 | 41 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1998 | 35 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2000 | 307 | 0.040 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2017 | 9 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 238 | 0.040 |
Why?
|
| Pregabalin | 1 | 2017 | 13 | 0.040 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2017 | 42 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2002 | 504 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 398 | 0.040 |
Why?
|
| Molar, Third | 1 | 1996 | 7 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 264 | 0.040 |
Why?
|
| Tooth Extraction | 1 | 1996 | 27 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 392 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 1998 | 88 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pentamidine | 1 | 1996 | 7 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 540 | 0.030 |
Why?
|
| Naphthoquinones | 1 | 1996 | 14 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 171 | 0.030 |
Why?
|
| Acute Disease | 2 | 2014 | 658 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1996 | 57 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 110 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 1996 | 23 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 1996 | 19 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 1996 | 43 | 0.030 |
Why?
|
| Rifabutin | 1 | 1995 | 5 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 68 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 16 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1465 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2006 | 57 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1995 | 11 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 108 | 0.030 |
Why?
|
| Cost Control | 1 | 2015 | 34 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1995 | 18 | 0.030 |
Why?
|
| Drug Approval | 1 | 1995 | 50 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 117 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2000 | 561 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1995 | 46 | 0.030 |
Why?
|
| Perfusion | 1 | 2015 | 131 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 214 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 2550 | 0.030 |
Why?
|
| Volunteers | 1 | 2014 | 30 | 0.030 |
Why?
|
| Restraint, Physical | 2 | 2005 | 59 | 0.030 |
Why?
|
| Probability | 1 | 1994 | 245 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1995 | 85 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 805 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 216 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2014 | 281 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1995 | 285 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 296 | 0.030 |
Why?
|
| Norwood Procedures | 1 | 2014 | 61 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2010 | 260 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2014 | 174 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 2013 | 44 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 1173 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 1992 | 11 | 0.030 |
Why?
|
| Nitrous Oxide | 1 | 1992 | 7 | 0.030 |
Why?
|
| Isoflurane | 1 | 1992 | 16 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1992 | 37 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 792 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 1992 | 15 | 0.030 |
Why?
|
| Fentanyl | 1 | 1992 | 26 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2011 | 39 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2000 | 1034 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 506 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 239 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1991 | 24 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1991 | 57 | 0.020 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2010 | 12 | 0.020 |
Why?
|
| Health Services Research | 1 | 1992 | 209 | 0.020 |
Why?
|
| Torque | 1 | 2010 | 34 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2010 | 33 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 281 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 8474 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 911 | 0.020 |
Why?
|
| Knee Joint | 1 | 2010 | 115 | 0.020 |
Why?
|
| Veterans | 1 | 2017 | 904 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 14 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 239 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2012 | 403 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 567 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 53 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2014 | 657 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1991 | 329 | 0.020 |
Why?
|
| Health Policy | 1 | 1991 | 221 | 0.020 |
Why?
|
| Nutritional Requirements | 1 | 2009 | 57 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 453 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 131 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 291 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2008 | 69 | 0.020 |
Why?
|
| Telephone | 1 | 2008 | 160 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2009 | 222 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 392 | 0.020 |
Why?
|
| Mortality | 1 | 2008 | 163 | 0.020 |
Why?
|
| Current Procedural Terminology | 1 | 2006 | 4 | 0.020 |
Why?
|
| Systole | 1 | 2006 | 149 | 0.020 |
Why?
|
| Diastole | 1 | 2006 | 161 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 867 | 0.020 |
Why?
|
| Alcoholic Intoxication | 1 | 2005 | 61 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 20881 | 0.020 |
Why?
|
| Athletic Injuries | 1 | 2005 | 73 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 1593 | 0.010 |
Why?
|
| Internal Medicine | 1 | 2005 | 118 | 0.010 |
Why?
|
| House Calls | 1 | 2004 | 15 | 0.010 |
Why?
|
| Community Health Services | 1 | 2004 | 141 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 438 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2005 | 586 | 0.010 |
Why?
|
| Alcohol-Related Disorders | 1 | 2003 | 95 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2005 | 328 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2000 | 104 | 0.010 |
Why?
|
| England | 1 | 2000 | 64 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 243 | 0.010 |
Why?
|
| Albuminuria | 1 | 2000 | 171 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2000 | 180 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 1998 | 16 | 0.010 |
Why?
|
| Registries | 1 | 2001 | 733 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1998 | 238 | 0.010 |
Why?
|
| Dysgeusia | 1 | 1996 | 4 | 0.010 |
Why?
|
| Mastication | 1 | 1996 | 7 | 0.010 |
Why?
|
| Atovaquone | 1 | 1996 | 2 | 0.010 |
Why?
|
| Edema | 1 | 1996 | 66 | 0.010 |
Why?
|
| Spirometry | 1 | 1996 | 47 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1996 | 12 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 215 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1996 | 328 | 0.010 |
Why?
|
| Perception | 1 | 1996 | 189 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1995 | 62 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1995 | 76 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1040 | 0.010 |
Why?
|
| Lung | 1 | 1996 | 849 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 2324 | 0.010 |
Why?
|